| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 80,400 | $1 | $321.6K |
| J0897 | Injection, denosumab, 1 mg | 14,760 | $20 | $265.7K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 3,780 | $30 | $128.3K |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 15,330 | $10 | $122.6K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2,970 | $30 | $80.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 670 | $90 | $59.3K |
| J1306 | Injection, inclisiran, 1 mg | 5,400 | $10 | $48.6K |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 4,450 | $10 | $44.5K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 710 | $60 | $39.8K |
| 99205 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider… | 100 | $160 | $15.6K |